Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
April 17, 2018 13:01 ET
|
Mersana Therapeutics, Inc.
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor CAMBRIDGE, Mass.,...
Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
April 09, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
March 28, 2018 07:30 ET
|
Mersana Therapeutics, Inc.
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2 Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting...
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
March 19, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Appoints David A. Spellman as Chief Financial Officer
March 12, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
February 07, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals
January 08, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 20, 2017 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Added to NASDAQ Biotechnology Index
December 15, 2017 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors
December 12, 2017 08:00 ET
|
Mersana Therapeutics, Inc.
Trial to Study Patients in Ovarian, NSCLC and Other Cancers XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) --...